Dose optimization is effective in ulcerative colitis patients losing response to infliximab

A collaborative multicentre retrospective study

Monica Cesarini, Konstantinos Katsanos, Konstantinos Papamichael, Pierre Ellul, P. Lakatos, Flavio Caprioli, Uri Kopylov, Epameinondas Tsianos, Gerassimos J. Mantzaris, Shomron Ben-Horin, Silvio Danese, Gionata Fiorino

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Subjects maintained on infliximab scheduled therapy for inflammatory bowel disease may require dose optimization due to secondary loss of response. There are limited data on infliximab dose optimization for ulcerative colitis. Aims: To investigate dose optimization in ulcerative colitis patients with secondary loss of response. Methods: This was a retrospective multicentre study. Primary outcome was rapid clinical response assessed at the next administration of infliximab after dose intensification. Secondary outcomes were rapid clinical remission, and clinical response, remission and colectomy rate by week 52. Doubling the dose (10. mg/kg q8 weeks) vs. shortening the dose interval (5. mg/kg every 6 or 4 weeks) were compared. Results: Forty-one patients from eight centres were enrolled (15 for double dose and 26 for interval shortening). Rapid response was achieved in 37/41 patients (90.2%), while 19/41 (46.3%) achieved rapid clinical remission. At week 52, 28/41 patients were maintained in clinical remission, but 4 (9.8%) underwent colectomy. No difference was found between the two optimization strategies. Subjects achieving rapid clinical response had a significantly higher colectomy-free rate at week 52 (p= 0.002). Conclusion: Dose optimization of infliximab was effective to restore clinical response or remission and to prevent colectomy in ulcerative colitis patients with secondary loss of response.

Original languageEnglish
Pages (from-to)135-139
Number of pages5
JournalDigestive and Liver Disease
Volume46
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Ulcerative Colitis
Colectomy
Multicenter Studies
Retrospective Studies
Inflammatory Bowel Diseases
Infliximab
Therapeutics

Keywords

  • Dose optimization
  • Infliximab
  • Loss of response
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Dose optimization is effective in ulcerative colitis patients losing response to infliximab : A collaborative multicentre retrospective study. / Cesarini, Monica; Katsanos, Konstantinos; Papamichael, Konstantinos; Ellul, Pierre; Lakatos, P.; Caprioli, Flavio; Kopylov, Uri; Tsianos, Epameinondas; Mantzaris, Gerassimos J.; Ben-Horin, Shomron; Danese, Silvio; Fiorino, Gionata.

In: Digestive and Liver Disease, Vol. 46, No. 2, 02.2014, p. 135-139.

Research output: Contribution to journalArticle

Cesarini, M, Katsanos, K, Papamichael, K, Ellul, P, Lakatos, P, Caprioli, F, Kopylov, U, Tsianos, E, Mantzaris, GJ, Ben-Horin, S, Danese, S & Fiorino, G 2014, 'Dose optimization is effective in ulcerative colitis patients losing response to infliximab: A collaborative multicentre retrospective study', Digestive and Liver Disease, vol. 46, no. 2, pp. 135-139. https://doi.org/10.1016/j.dld.2013.10.007
Cesarini, Monica ; Katsanos, Konstantinos ; Papamichael, Konstantinos ; Ellul, Pierre ; Lakatos, P. ; Caprioli, Flavio ; Kopylov, Uri ; Tsianos, Epameinondas ; Mantzaris, Gerassimos J. ; Ben-Horin, Shomron ; Danese, Silvio ; Fiorino, Gionata. / Dose optimization is effective in ulcerative colitis patients losing response to infliximab : A collaborative multicentre retrospective study. In: Digestive and Liver Disease. 2014 ; Vol. 46, No. 2. pp. 135-139.
@article{eb2b68e0c3564d6582054efec993cb07,
title = "Dose optimization is effective in ulcerative colitis patients losing response to infliximab: A collaborative multicentre retrospective study",
abstract = "Background: Subjects maintained on infliximab scheduled therapy for inflammatory bowel disease may require dose optimization due to secondary loss of response. There are limited data on infliximab dose optimization for ulcerative colitis. Aims: To investigate dose optimization in ulcerative colitis patients with secondary loss of response. Methods: This was a retrospective multicentre study. Primary outcome was rapid clinical response assessed at the next administration of infliximab after dose intensification. Secondary outcomes were rapid clinical remission, and clinical response, remission and colectomy rate by week 52. Doubling the dose (10. mg/kg q8 weeks) vs. shortening the dose interval (5. mg/kg every 6 or 4 weeks) were compared. Results: Forty-one patients from eight centres were enrolled (15 for double dose and 26 for interval shortening). Rapid response was achieved in 37/41 patients (90.2{\%}), while 19/41 (46.3{\%}) achieved rapid clinical remission. At week 52, 28/41 patients were maintained in clinical remission, but 4 (9.8{\%}) underwent colectomy. No difference was found between the two optimization strategies. Subjects achieving rapid clinical response had a significantly higher colectomy-free rate at week 52 (p= 0.002). Conclusion: Dose optimization of infliximab was effective to restore clinical response or remission and to prevent colectomy in ulcerative colitis patients with secondary loss of response.",
keywords = "Dose optimization, Infliximab, Loss of response, Ulcerative colitis",
author = "Monica Cesarini and Konstantinos Katsanos and Konstantinos Papamichael and Pierre Ellul and P. Lakatos and Flavio Caprioli and Uri Kopylov and Epameinondas Tsianos and Mantzaris, {Gerassimos J.} and Shomron Ben-Horin and Silvio Danese and Gionata Fiorino",
year = "2014",
month = "2",
doi = "10.1016/j.dld.2013.10.007",
language = "English",
volume = "46",
pages = "135--139",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Dose optimization is effective in ulcerative colitis patients losing response to infliximab

T2 - A collaborative multicentre retrospective study

AU - Cesarini, Monica

AU - Katsanos, Konstantinos

AU - Papamichael, Konstantinos

AU - Ellul, Pierre

AU - Lakatos, P.

AU - Caprioli, Flavio

AU - Kopylov, Uri

AU - Tsianos, Epameinondas

AU - Mantzaris, Gerassimos J.

AU - Ben-Horin, Shomron

AU - Danese, Silvio

AU - Fiorino, Gionata

PY - 2014/2

Y1 - 2014/2

N2 - Background: Subjects maintained on infliximab scheduled therapy for inflammatory bowel disease may require dose optimization due to secondary loss of response. There are limited data on infliximab dose optimization for ulcerative colitis. Aims: To investigate dose optimization in ulcerative colitis patients with secondary loss of response. Methods: This was a retrospective multicentre study. Primary outcome was rapid clinical response assessed at the next administration of infliximab after dose intensification. Secondary outcomes were rapid clinical remission, and clinical response, remission and colectomy rate by week 52. Doubling the dose (10. mg/kg q8 weeks) vs. shortening the dose interval (5. mg/kg every 6 or 4 weeks) were compared. Results: Forty-one patients from eight centres were enrolled (15 for double dose and 26 for interval shortening). Rapid response was achieved in 37/41 patients (90.2%), while 19/41 (46.3%) achieved rapid clinical remission. At week 52, 28/41 patients were maintained in clinical remission, but 4 (9.8%) underwent colectomy. No difference was found between the two optimization strategies. Subjects achieving rapid clinical response had a significantly higher colectomy-free rate at week 52 (p= 0.002). Conclusion: Dose optimization of infliximab was effective to restore clinical response or remission and to prevent colectomy in ulcerative colitis patients with secondary loss of response.

AB - Background: Subjects maintained on infliximab scheduled therapy for inflammatory bowel disease may require dose optimization due to secondary loss of response. There are limited data on infliximab dose optimization for ulcerative colitis. Aims: To investigate dose optimization in ulcerative colitis patients with secondary loss of response. Methods: This was a retrospective multicentre study. Primary outcome was rapid clinical response assessed at the next administration of infliximab after dose intensification. Secondary outcomes were rapid clinical remission, and clinical response, remission and colectomy rate by week 52. Doubling the dose (10. mg/kg q8 weeks) vs. shortening the dose interval (5. mg/kg every 6 or 4 weeks) were compared. Results: Forty-one patients from eight centres were enrolled (15 for double dose and 26 for interval shortening). Rapid response was achieved in 37/41 patients (90.2%), while 19/41 (46.3%) achieved rapid clinical remission. At week 52, 28/41 patients were maintained in clinical remission, but 4 (9.8%) underwent colectomy. No difference was found between the two optimization strategies. Subjects achieving rapid clinical response had a significantly higher colectomy-free rate at week 52 (p= 0.002). Conclusion: Dose optimization of infliximab was effective to restore clinical response or remission and to prevent colectomy in ulcerative colitis patients with secondary loss of response.

KW - Dose optimization

KW - Infliximab

KW - Loss of response

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84893691878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893691878&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2013.10.007

DO - 10.1016/j.dld.2013.10.007

M3 - Article

VL - 46

SP - 135

EP - 139

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 2

ER -